Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Eli Lilly's Onswik (insulin efsitora alfa-gobe) for type 2 diabetes in Ph3-backed once-weekly insulin
Protein therapy, metabolic, insulin, type 2 diabetes, weekly injection - Read more

FDA approves Elevar Therapeutics' Lyrfigtu (lirafugratinib) for FGFR2-altered cholangiocarcinoma based on Ph1/Ph2 data
Small molecule, cancer, FGFR inhibitor, cholangiocarcinoma, FGFR2 fusion - Read more

Henlius Biotech, Amberstone Biosciences strike $440M T-cell engager deal using T-Mate platform
Licensing deal, oncology, T-cell engager, antibody, milestone payments, royalties - Read more

Eli Lilly, InnoCare Pharma partner on five unmet need targets, $100M upfront, $3.25B milestones
Co-development, oncology, autoimmune, drug discovery, milestone payments, royalties - Read more

Roche, Atavistik Bio partner on cardiometabolic small molecule drug discovery, $70M upfront, $1.9B milestones
Research collaboration, cardiometabolic, small molecule, drug discovery, milestone payments, royalties - Read more

Flen Health selects AGC Biologics as CDMO for recombinant enzyme wound treatment manufacturing and clinical trials
Manufacturing agreement, wound care, recombinant proteins, CDMO, microbial manufacturing - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Kyverna Therapeutics reports 1-year Ph3 miv-cel (mivocabtagene autoleucel) data showing durable efficacy in stiff person syndrome with clean safety profile
Cell therapy, autoimmune, CAR-T, stiff person syndrome, myasthenia gravis, cytokine release syndrome - Read more

Merck & Co.'s (remigromig) meets primary endpoint in Ph2b/3 trial for diabetic macular edema, Wnt pathway agonist shows noninferiority
Protein therapy, ophthalmology, trispecific antibody, diabetic macular edema, Wnt signaling pathway, VEGF inhibitor - Read more

ImmuneOnco Biopharmaceuticals' (amulirafusp alfa) targeting CD47/CD20 shows 92.3% overall response rate in Ph1b/2a marginal zone lymphoma trial
Antibody, cancer, myeloid cell engager, non-Hodgkin lymphoma, CD47, combination therapy - Read more

Basecamp Research raises $140M Series C to advance AI-designed drug pipeline
AI/ML platform, drug discovery, cell therapy, gene therapy, platform-enabled - Read more

BigHat Biosciences raises $75M Series C, advancing AI-designed biologic pipeline
AI/ML platform, antibody-drug conjugate, protein design, oncology, clinical-stage - Read more

Tempo Therapeutics receives $2.25M NIH SBIR grant to advance MAP Wound Matrix clinical study
Regenerative medicine, synthetic biomaterials, wound healing, clinical-stage - Read more

Big Picture Bio raises £1.5M (~$2M) Pre-Seed funding to expand operations and R&D efforts
Cancer, AI/ML platform, drug discovery, combination therapy, preclinical - Read more

United Immunity raises ¥2.2B (~$13.9M), advancing macrophage engineering programs for solid tumors and fibrosis
Myeloid targeting, nanoparticle, oncology, fibrosis, autoimmune, clinical-stage - Read more

ArcaScience launches Flow AI software to automate drug benefit-risk assessments and regulatory submissions
AI software, drug safety, regulatory, operational - Read more

Grail's Galleri multi-cancer blood test receives positive FDA advisory committee recommendation for adults aged 50 and over
Diagnostic test, cancer, liquid biopsy, multi-cancer early detection, screening - Read more

Novo CEO open to NYSE listing to attract U.S. investors amid market share pressure
Stock listing, GLP-1, strategic, financial, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Acadia Pharmaceuticals' (remlifanserin) Ph2 misses primary endpoint in Alzheimer's disease psychosis, Ph3 continues
Small molecule, neurological, inverse agonist, Alzheimer's disease, psychosis, 5HT2A receptor - Read more

Adagio Medical launches strategic review, cuts over half its workforce amid Nasdaq delisting threat
Cryoablation device, cardiovascular, strategic, cost reduction - Read more

Otsuka ICU Medical recalls one sodium chloride lot over potassium chloride mislabeling, risking fatal outcomes
IV solutions, patient safety, operational, recall - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here